Organization | People's Hospital of Quzhou

People's Hospital of Quzhou Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Quzhou China (1948)

Organization Overview

First Clinical Trial

2015

NCT04202068

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

People's Hospital of Quzhou | The People's Hospital of Quzhou City

Active Ingredients

Drugs in Phase 4 Trials (7)

carboplatin (paraplatin) (1 trial)

ceftriaxone (rocephin) (1 trial)

cisplatin (platinol) (2 trials)

gemcitabine (gemzar) (1 trial)

sintilimab (1 trial)

sulbactam (unasyn) (1 trial)

xingnaojing (1 trial)

Drugs in Phase 3 Trials (4)

bat5906 (1 trial)

docetaxel (taxotere) (1 trial)

mifepristone (mifeprex) (1 trial)

ranibizumab (lucentis) (1 trial)

Drugs in Phase 2 Trials (1)

camrelizumab (1 trial)

Drugs in Phase 1 Trials (1)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenomyosis (Phase 3)

Carcinoma (Phase 3)

Cerebral Infarction (Phase 4)

Gonorrhea (Phase 4)

Ischemia (Phase 4)

Nasopharyngeal Carcinoma (Phase 3)

Stroke (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 13